Key result
An opioid-sparing anesthesia and ERAS protocol for pancreaticoduodenectomy significantly decreased hospital length of stay by 3.2 days and reduced opioid requirements by 45% during the first five hospital days.
Why the study?
The utilization of opioid-sparing anesthesia and enhanced recovery after surgery protocols for pancreaticoduodenectomy is limited despite the need to limit opioid-related adverse effects and curb postoperative opioid use.
Does an opioid-sparing anesthesia and ERAS protocol reduce hospital length of stay and opioid requirements in patients undergoing elective pancreaticoduodenectomy?
Cohort (n=50)
No
Does an opioid-sparing anesthesia and ERAS protocol reduce hospital length of stay and opioid requirements in patients undergoing elective pancreaticoduodenectomy?
An opioid-sparing anesthesia and ERAS protocol for pancreaticoduodenectomy significantly reduced hospital length of stay, ICU days, and postoperative opioid consumption without increasing 30-day readmissions.
Answers are grounded in this paper and cite their sources.
May support opioid-sparing ERAS protocols in pancreaticoduodenectomy; hypothesis-generating and requires RCTs before practice change.
Background Opioid sparing anesthesia and enhanced recovery after surgery protocols are not innovative ideas. However, the utilization of pancreaticoduodenectomy is limited. With the rise in awareness of the opioid epidemic in the United States, we have created a multimodal approach to anesthesia and postoperative care to limit adverse effects of opioids and curb the use of opioids postoperatively. Methods We conducted a retrospective cohort study performed by chart review of an opioid-sparing anesthetic and enhanced recovery after surgery (ERAS) protocol initiated jointly by the anesthesiology departments and transplant surgery for pancreaticoduodenectomy from January 2017 to October 2019. Results Demographic data was found to be comparable between the control and protocol groups. Hospital length of stay, ICU length of stay, and opioid requirements significantly decreased in the protocol group. Hospital length of stay decreased from 8.92 to 5.72 days, ICU days decreased from 1.52 to 0.42 days, and narcotics for the first five hospital days were significantly decreased from 130.13 to 71.2 morphine milligram equivalents. Conclusion Proper postoperative pain management can improve patient satisfaction and decrease complication rates. Pancreaticoduodenectomy is a complicated procedure with relatively limited data regarding enhanced recovery after surgery protocols. Likewise, there is limited data regarding opioid-sparing anesthesia techniques. Our protocol produced promising hospital length of stay and reduced opioid administration during the first five hospital days without increasing 30-day readmission rates.
No takes yet. Share an insight, caveat, or question.
Leech et al. (2021) conducted a cohort in Pancreaticoduodenectomy (n=50). Opioid-sparing anesthesia and enhanced recovery after surgery (ERAS) protocol vs. Conventional methods was evaluated on Hospital length of stay (3.2-day decrease, p=0.008). An opioid-sparing anesthesia and ERAS protocol for pancreaticoduodenectomy significantly decreased hospital length of stay by 3.2 days and reduced opioid requirements by 45% during the first five hospital days.
Synapse has enriched 10 related papers. Consider them for comparative context: